Rocket Pharmaceuticals Inc
RCKT3.030USD
+0.039+1.32%
交易中 （美東）報價延遲15分鐘
323.41M總市值
虧損本益比TTM
關於 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的後期生物技術公司。該公司正在推進一系列可持續的試驗性基因療法，旨在糾正複雜和罕見疾病的根本原因。其基於慢病毒 (LV) 載體的基因療法針對血液病，包括針對範康尼貧血症（一種難以治療的遺傳病，會導致骨髓衰竭和潛在的癌症）、白細胞粘附缺陷-I (LAD-I)（一種嚴重的兒科遺傳病，會導致反覆發作且危及生命的感染，這些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一種單基因紅細胞疾病，導致紅細胞破壞增加和輕度至危及生命的貧血）的後期項目。該公司還有兩個臨牀階段和一個臨牀前階段的體內腺相關病毒 (AAV) 項目，包括針對 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 擴張型心肌病的項目。
公司簡介
公司代碼RCKT
公司名稱Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
員工數量299
證券類型Ordinary Share
年結日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編08512
電話16464409100
網址https://www.rocketpharma.com/
公司代碼RCKT
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
30.00K
--
Mr. Piratip Pratumsuwan
Mr. Piratip Pratumsuwan
Independent Director
Independent Director
30.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月7日 週六
更新時間: 6月7日 週六
持股股東
股東類型
持股股東
持股股東
佔比
RTW Investments L.P.
16.42%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Westfield Capital Management Company, L.P.
4.47%
Other
62.12%
持股股東
持股股東
佔比
RTW Investments L.P.
16.42%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Westfield Capital Management Company, L.P.
4.47%
Other
62.12%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
39.42%
Investment Advisor
25.32%
Hedge Fund
18.42%
Research Firm
4.48%
Individual Investor
2.86%
Bank and Trust
1.28%
Venture Capital
1.25%
Private Equity
1.13%
Pension Fund
0.19%
Other
5.66%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
491
101.70M
94.39%
-14.34M
2025Q1
494
114.28M
106.44%
-9.69M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
2023Q1
419
83.81M
105.83%
-4.94M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
17.69M
16.42%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.60M
6.13%
+40.19K
+0.61%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.15M
5.71%
+514.15K
+9.13%
Mar 31, 2025
Maverick Capital, Ltd.
5.55M
5.15%
+347.96K
+6.69%
Apr 07, 2025
Westfield Capital Management Company, L.P.
4.82M
4.47%
+106.09K
+2.25%
Mar 31, 2025
State Street Global Advisors (US)
3.71M
3.44%
+247.38K
+7.15%
Mar 31, 2025
Suvretta Capital Management, LLC
3.50M
3.25%
+935.05K
+36.43%
Mar 31, 2025
Janus Henderson Investors
3.29M
3.05%
-713.20K
-17.81%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.96M
2.75%
-127.10K
-4.11%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.99M
1.85%
+241.07K
+13.75%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Harbor Health Care ETF
0.65%
WisdomTree BioRevolution Fund
0.34%
Global X Genomics & Biotechnology ETF
0.31%
Tema Heart & Health ETF
0.16%
Main Thematic Innovation ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.72%
Harbor Health Care ETF
佔比0.65%
WisdomTree BioRevolution Fund
佔比0.34%
Global X Genomics & Biotechnology ETF
佔比0.31%
Tema Heart & Health ETF
佔比0.16%
Main Thematic Innovation ETF
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Biotechnology ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Fidelity Enhanced Small Cap ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
